Breaking News Instant updates and real-time market news.

SBUX

Starbucks

$52.70

-0.34 (-0.64%)

, LMT

Lockheed Martin

$299.20

-2.22 (-0.74%)

20:02
08/20/17
08/20
20:02
08/20/17
20:02

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. B&G Foods (BGS) has entered into a definitive agreement to acquire Back to Nature Foods Company from Brynwood Partners, Mondelez (MDLZ) and certain other entities and individuals for approximately $162.5M in cash. B&G Foods expects the acquisition to close during Q3 of 2017. 2. Sempra Energy (SRE) is nearing an agreement to buy Oncor Electric Delivery for about $9.3B, according to Bloomberg, citing people familiar with the matter. The Texas utility is also being pursued by Warren Buffett's Berkshire Hathaway (BRK.A) and Paul Singer's Elliott Management, the publication noted. 3. Starbucks' (SBUX) mobile order-and-pay feature has become a major hit, Alex Eule wrote in this week's edition of Barron's. In the last quarter, 9% of Starbucks' U.S. orders were placed in advance, and nearly a third of all its orders were paid for via the company's phone app, the publication noted. Eule believes that the stock could jump 20% or more over the next 12 months. 4. Lionsgate's (LGF.A) action comedy "Hitman's Bodyguard" debuted to a better than expected $21.6M from 3,377 theaters to top the weekend box-office chart, as summer revenue continues to tumble. The movie tells the story of a world-renowned bodyguard who is forced to protect an infamous hitman that is scheduled to testify. With a 38% rating on Rotten Tomatoes, "Hitman's Bodyguard" received a B+ CinemaScore rating by audiences. 5. Lockheed Martin (LMT), Gardner Denver (GDI), Cardinal Health (CAH), Patterson Companies (PDCO), ResMed (RMD), AmerisourceBergen (ABC), UnitedHealth (UNH), and Advance Auto Parts (AAP) saw positive mentions in Barron's, while Motorola Solutions (MSI) was mentioned cautiously.

SBUX

Starbucks

$52.70

-0.34 (-0.64%)

LMT

Lockheed Martin

$299.20

-2.22 (-0.74%)

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

CAH

Cardinal Health

$64.38

-0.78 (-1.20%)

PDCO

Patterson Companies

$36.45

-0.31 (-0.84%)

RMD

ResMed

$73.07

0.28 (0.38%)

ABC

AmerisourceBergen

$78.60

-1.34 (-1.68%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

LGF.A

Lionsgate

$28.41

0.37 (1.32%)

BGS

B&G Foods

$31.40

-0.3 (-0.95%)

MDLZ

Mondelez

$42.94

-0.47 (-1.08%)

SRE

Sempra Energy

$116.55

0.76 (0.66%)

BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

  • 22

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

  • 06

    Sep

  • 11

    Sep

  • 14

    Sep

  • 18

    Sep

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 02

    Nov

  • 25

    Jan

SBUX Starbucks
$52.70

-0.34 (-0.64%)

08/09/17
08/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) downgraded on more cautious U.S. comp sales outlook at BMO Capital with analyst Andrew Strelzik saying he's "more cautious" on the outlook for the company's U.S. comparable sales, partly due to increased cannibalization of stores, increased competition, "throughput headwinds," and the possibility that "contributions from beverage innovation and food growth may have peaked." 2. Albemarle (ALB) downgraded to Hold from Buy at SunTrust with analyst James Sheehan citing recent share strength. 3. Dean Foods (DF) downgraded to Market Perform from Outperform at Wells Fargo with analyst John Baumgartnerm citing the second quarter miss and "big" guidance reduction. 4. Air Lease (AL) downgraded to Neutral from Buy at BofA/Merrill with analyst Kristine Liwag citing valuation. 5. AIG (AIG) downgraded to Neutral from Overweight at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/09/17
BMOC
08/09/17
DOWNGRADE
BMOC
Market Perform
Starbucks downgraded on more cautious U.S. comp sales outlook at BMO Capital
As noted earlier, BMO Capital downgraded Starbucks to Market Perform from Outperform. Analyst Andrew Strelzik says he's "more cautious" on the outlook for the company's U.S. comp sales, partly due to increased cannibalization of stores, increased competition, "throughput headwinds," and the possibility that "contributions from beverage innovation and food growth may have peaked."
08/09/17
BMOC
08/09/17
DOWNGRADE
BMOC
Market Perform
Starbucks downgraded to Market Perform from Outperform at BMO Capital
07/28/17
07/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) was downgraded to Neutral from Buy at Guggenheim and to Hold from Buy at Stifel. 2. Spirit Airlines (SAVE) was downgraded to Neutral from Buy at Buckingham and BofA/Merrill and to In-Line from Outperform at Imperial Capital. 3. Flowers Foods (FLO) downgraded to Hold from Buy at Jefferies with analyst Akshay Jagdale saying his positive thesis on bread industry pricing becoming more rational has not played out. 4. AstraZeneca (AZN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Vincent Meunier saying shares look fairly valued as he removed MYSTIC from his models. 5. U.S. Steel (X) downgraded to Sell from Neutral at Citi with analyst Alexander Hacking saying he sees downside risk to U.S. flat rolled prices for the remainder of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LMT Lockheed Martin
$299.20

-2.22 (-0.74%)

08/08/17
MSCO
08/08/17
INITIATION
Target $342
MSCO
Overweight
Lockheed Martin initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated Lockheed Martin with an Overweight and a $342 price target saying it has the right balance of segment margin growth, revenue visibility, and leading 5-year CAGR, all supported by the F-35 ramp over the coming years, combined with pension benefits.
08/08/17
08/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN), Alphabet (GOOG, GOOGL), and Facebook (FB) were reinstated with a Buy at Mizuho, while eBay (EBAY) and Twitter (TWTR) were reinstated with an Underperform. 2. Broadridge (BR) initiated with a Neutral at DA Davidson. 3. Brighthouse Financial (BHF) initiated with an Overweight at Barclays. 4. Akcea Therapeutics (AKCA) WAS initiated with an Outperform at BMO Capital and Cowen, an Outperform at Wells Fargo, as well as a Buy at Stifel. 5. Lockheed Martin (LMT) and Raytheon (RTN) were initiated with an Overweight at Morgan Stanley, while Northrop Grumman (NOC) was initiated with an Equal Weight, and General Dynamics (GD) was initiated with an Underweight at the firm. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/17
ARGS
07/19/17
NO CHANGE
ARGS
Lockheed Martin price target raised to $320 from $290 at Argus
Argus analyst John Eade increased his price target on Lockheed Martin after the company reported higher than expected Q2 EPS. The analyst notes that U.S. defense spending is rising, while geopolitical tensions are increasing. Calling the stock's valuation attractive, he keeps a Buy rating on the shares.
08/14/17
SBSH
08/14/17
NO CHANGE
SBSH
Buy
Lockheed wins $8B contract over L3 and CACI, says Citi
Citi analyst Jason Gursky says the U.S. Special Ops Command Friday after the close awarded the Special Operations Forces Global Logistics Support Services contract to incumbent Lockheed Martin (LMT) over L3 Technologies (LLL), CACI (CACI) and potentially others. The $8B contract over multiple years is a positive development for Lockheed's MFC segment and an "incremental negative" for L3, the analyst tells investors in a research note. He believes CACI's bid "was always a long shot given the level of competition." Gursky has Buy ratings on all three names.
GDI Gardner Denver
$21.97

-0.03 (-0.14%)

06/06/17
TIGR
06/06/17
INITIATION
TIGR
Buy
Gardner Denver initiated with a Buy at Tigress Financial
Tigress Financial analyst Ivan Feinseth initiated Gardner Denver with a Buy rating, citing its competitive advantage, installed base and growing aftermarket platform.
06/06/17
06/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hartford Financial (HIG) initiated with a Buy at Deutsche Bank. 2. FedEx (FDX) and UPS (UPS) were initiated with a Neutral at Seaport Global. 3. Gardner Denver (GDI) was initiated with an Outperform at William Blair and Baird, an Overweight at Piper Jaffray, a Buy at Stifel, UBS, and Goldman Sachs, as well as a Neutral at Credit Suisse. 4. Solaris Oilfield (SOI) was initiated with an Outperform at Wells Fargo, Oppenheimer, Evercore ISI, and Credit Suisse, an Overweight at Piper Jaffray, as well as a Buy at Goldman Sachs and Wunderlich. 5. LeMaitre (LMAT) initiated with a Hold at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
WBLR
06/06/17
INITIATION
WBLR
Outperform
Gardner Denver initiated with an Outperform at William Blair
William Blair analyst Brian Drab started Gardner Denver with an Outperform rating.
07/11/17
WOLF
07/11/17
INITIATION
Target $26
WOLF
Outperform
Gardner Denver initiated with an Outperform at Wolfe Research
Wolfe Research initiated Gardner Denver with an Outperform and a$26 price target.
CAH Cardinal Health
$64.38

-0.78 (-1.20%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $87
FBCO
Outperform
Cardinal Health price target raised to $87 from $81 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Cardinal Health to $87 from $81 given the company's recent acquisition of Medtronic's patient recovery business. The analyst reiterates an Outperform rating on the shares.
08/09/17
BARD
08/09/17
NO CHANGE
BARD
Neutral
AmerisourceBergen settlement ups odds of PharMerica switch, says Baird
Baird analyst Eric Coldwell said AmerisourceBergen's (ABC) 10-Q last week showed that the company and PharMerica (PMC) have tentatively agreed to settle their long-running legal fight, which he reads as significantly increasing the odds of AmerisourceBergen displacing incumbent Cardinal Health (CAH) after KKR (KKR) and minority investor Walgreens (WBA) complete their deal to buy PharMerica. Coldwell has a Neutral rating and $89 price target on AmerisourceBergen shares.
07/03/17
BARD
07/03/17
NO CHANGE
Target $75
BARD
Neutral
Cardinal Health confirms deal to buy Liberty Medical, says Baird
Baird analyst Eric Coldwell said that Cardinal Health has confirmed a deal to buy Liberty Medical, a direct-to-patient provider of diabetes supplies and products that is well known for its commercials featuring actor Wilford Brimley. The small deal, which is immaterial to his model, enhances Cardinal's direct-to-patient platform primarily in diabetes and likely also adds volume in ostomy and urology, Coldwell tells investors. He keeps a Neutral rating and $75 price target on Cardinal Health shares.
08/03/17
FBCO
08/03/17
NO CHANGE
Target $81
FBCO
Outperform
Cardinal Health price target lowered to $81 from $87 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for Cardinal Health to $81 from $87, citing on a "surprising" cut to 2018 EPS guidance primarily on incremental investment initiatives across its businesses, further defining 2018 as a transition year. The analyst reiterates an Outperform rating on the shares.
PDCO Patterson Companies
$36.45

-0.31 (-0.84%)

08/01/17
NRCS
08/01/17
NO CHANGE
Target $76
NRCS
Buy
Dentsply Sirona estimaters reduced at Northcoast
Northcoast analyst Ed Snyder's checks indicate Patterson Companies (PDCO) sales of high technology dental equipment is weaker than expected caused by industry competition. Snyder said it appears Patterson's CEREC sales growth is down about 40-50%, despite promotional activity. As a result, he reduced Dentsply Sirona's (XRAY) second half internal growth estimate to 1.4% from 2.3% and earnings FY17 earnings estimate to $2.80 from $2.82. Snyder retains a Buy rating on Dentsply and a $76 price target.
07/26/17
GSCO
07/26/17
NO CHANGE
GSCO
Dental survey indicates Q2 upside for Align, Henry Schein, says Goldman Sachs
Goldman analyst Robert Jones said checks indicate Q2 Dental trends remained stable and point to consistent low-single-digit growth end-markets. The analyst likes Align Technology (ALGN) saying Q2 case guidance appears beatable and expects high 20% case growth driven by investments, sees Q2 upside for Henry Schein (HSIC) due to share gains from Patterson Companies (PDCO), and said Dentsply Sirona (XRAY) promotions to drive cross-selling have yet to gain traction and 2017 guidance may be aggressive, but expectations are low into the quarter.
08/17/17
CHLM
08/17/17
NO CHANGE
Target $41
CHLM
Hold
Patterson Companies price target lowered to $41 from $46 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich lowered his price target for Patterson Companies(PDCO) to $41 from $46 to reflect the soft dental consumable environment and potential market share losses once Henry Schein (HSIC) starts to sell CEREC on September 1. Given the lower valuation and good, stable end markets, the analyst thinks Patterson Companies could be an "interesting target" for a financial buyer as cash flow should start to improve over the next few quarters once the company completes the ERP implementation. He reiterates a Hold rating on Patterson Companies' shares.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $50
FBCO
Outperform
Patterson Companies price target raised to $50 from $45 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Patterson Companies to $50 from $45 to be more in line with industry peers. The analyst reiterates an Outperform rating on the shares.
RMD ResMed
$73.07

0.28 (0.38%)

08/02/17
BOFA
08/02/17
DOWNGRADE
BOFA
Neutral
ResMed downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst William Dunlop downgraded ResMed to Neutral with a reduced price target of A$9.90. The analyst says the company's FY18 gross margin range of around 58.2% lessen his enthusiasm for its CPAP business prospects.
08/02/17
08/02/17
DOWNGRADE

Neutral
ResMed downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Saul Hadassin downgraded ResMed to Neutral from Outperform following the company's Q4 in line earnings. The analyst also lowered his price target on the shares to A$9.40 from A$9.70.
08/02/17
SBSH
08/02/17
UPGRADE
SBSH
Buy
ResMed upgraded to Buy from Neutral at Citi
Citi analyst Victor Windeyer upgraded ResMed to Buy with following the company's Q4 results. Credit Suisse and BofA/Merrill downgraded the shares this morning. The analyst believes supply bottlenecks have been removed and that the mask category can return to growth. He raised his price target for ResMed shares to A$10.50 from A$10.
08/02/17
08/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term." 2. Burlington Stores (BURL) downgraded to Neutral from Outperform at Credit Suisse with analyst Christian Buss saying that although the fundamentals of the company remain healthy, he sees limited upside to valuation as the multiples stay elevated despite more moderate industry growth prospects. 3. Big 5 Sporting (BGFV) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Baker saying he expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." 4. Ultimate Software (ULTI) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi calling the second quarter results "mixed" and prefers to move to the sidelines until growth returns to the mid-20s target and leverage returns to the model. 5. ResMed (RMD) was downgraded to Neutral from Buy at BofA/Merrill and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABC AmerisourceBergen
$78.60

-1.34 (-1.68%)

08/02/17
LEER
08/02/17
NO CHANGE
LEER
AmerisourceBergen may benefit from PharMerica takeover, says Leerink
Leerink analyst David Larsen believes AmerisourceBergen (ABC) could benefit from KKR's (KKR) buyout of PharMerica (PMC). KKR and Walgreens Boots Alliance (WBA), which uses AmerisourceBergen as a supplier, are forming a new private company which would hold PharMerica, Larsen tells investors in a research note. He believes PharMerica may switch away from its current supplier Cardinal Health (CAH) as a result of today's deal and use AmerisourceBergen. Any potential change in distributor contracts would likely occur in the second half of 2018, the analyst adds.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $105
FBCO
Outperform
AmerisourceBergen price target raised to $105 from $95 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for AmerisourceBergen to $105 from $95 to be more in line with the distributor group average. The analyst reiterates an Outperform rating on the shares.
08/07/17
LEER
08/07/17
NO CHANGE
Target $90
LEER
Outperform
AmerisourceBergen price target lowered to $90 from $100 at Leerink
Leerink analyst David Larsen lowered his price target for AmerisourceBergen to $90 from $100 noting that while its Q3 earnings results were largely in-line with consensus and guidance, the stock has sold off due to a lack of clarity around guidance for 2018. Nonetheless, the analyst reiterates an Outperform rating on the shares.
UNH UnitedHealth
$190.82

-1.88 (-0.98%)

08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Overweight
UnitedHealth made 'solid choice' in new CEO, says Piper Jaffray
Piper Jaffray analyst Sarah James views UnitedHealth's promotion of David Wichmann as a "solid choice and not a surprise." The analyst expects business as usual for the company as it continues to push into technology including artificial intelligence. She has an Overweight rating on the shares.
08/11/17
COWN
08/11/17
NO CHANGE
Target $220
COWN
Outperform
UnitedHealth price target raised to $220 from $175 at Cowen
Cowen analyst Christine Arnold raised her price target on UnitedHealth to $220 from $175. The analyst believes the company can achieve its long-term growth targets in 2018, citing Medicare Advantage enrollment growth, operating efficiencies, commercial market penetration, and OptumRx and OptumInsight earnings gains. Arnold reiterated her Outperform rating on UnitedHealth shares.
07/19/17
UBSW
07/19/17
NO CHANGE
Target $213
UBSW
Buy
UnitedHealth price target raised to $213 from $194 at UBS
UBS analyst A.J. Rice raised his price target on UnitedHealth to $213 from $194 following Q2 earnings. The analyst cited the company's positive outlook to gain market share in both group and individual Medicare Advantage markets along with continued growth assumptions for Optum Rx. Rice reiterated his Buy rating on UnitedHealth shares.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
AAP Advance Auto Parts
$93.26

0.41 (0.44%)

08/16/17
ATLE
08/16/17
DOWNGRADE
Target $93
ATLE
Neutral
Advance Auto Parts downgraded to Neutral from Overweight at Atlantic Equities
Atlantic Equities analyst Sam Hudson downgraded Advance Auto Parts to Neutral from Overweight with a $93 price target citing limited near-term visibility. Hudson said the challenging industry backdrop has pushed out a turnaround until FY18 at the earliest and said negative comps will persist in the second half and near-term margins are difficult to gauge.
08/16/17
DBAB
08/16/17
NO CHANGE
Target $101
DBAB
Buy
Deutsche Bank sticking with Buy rating on Advance Auto Parts
Deutsche Bank analyst Mike Baker lowered his price target to $101 from $139 following the Q2 results but is sticking with his Buy rating on Advance Auto Parts. First and most importantly, the company seems to be stabilizing its market share, the first step in any turnaround, Baker tells investors in a post-earnings research note. He also believes downward earnings revisions should be behind the company and that the current share price assumes little margin recovery.
08/16/17
GABE
08/16/17
NO CHANGE
GABE
Buy
Advance Auto Parts weakness a buying opportunity, says Gabelli
08/16/17
08/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dick's Sporting (DKS) was downgraded to Neutral from Buy at Monness Crespi, Goldman Sachs, MKM Partners, Buckingham, Citi, and to Neutral from Positive at Susquehanna, while being downgraded to Hold from Buy at Deutsche Bank and to Sector Perform from Outperform at RBC Capital. 2. Teva (TEVA) downgraded to Neutral from Buy at Citi with analyst Liav Abraham saying Teva is "cheap, but not cheap enough." 3. Advance Auto Parts (AAP) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing limited near-term visibility. 4. SL Green Realty (SLG) and Kilroy Realty (KRC) were downgraded to Neutral from Buy at BofA/Merrill, while Gramercy Property Trust (GPT) was downgraded to Underperform from Neutral. 5. CB&I (CBI) downgraded to Hold from Buy at Jefferies with analyst Martin Englert saying he is concerned that cost overruns at the company's two LNG projects could reemerge, adding risk to 2017-2019 earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MSI Motorola Solutions
$87.37

0.24 (0.28%)

05/30/17
NRCS
05/30/17
UPGRADE
NRCS
Buy
Motorola Solutions upgraded to Buy from Neutral at Northcoast
05/22/17
05/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Neutral at JPMorgan with analyst Rod Hall saying while more negative news from the Apple (AAPL) royalty suit is likely, "material fundamental upside" exists from the closure of the NXP Semiconductors (NXPI) by the end of this year. The analyst views the deal as highly accretive. Hall also believes Apple ultimately will want to preserve its commercial relationship with Qualcomm. 2. Motorola Solutions (MSI) upgraded to Outperform from Market Perform at Raymond James with analyst Tavis McCourt saying shares look increasingly attractive based on improved demand visibility that is less economically sensitive than many of its peers, and demand catalysts from FirstNet buildouts that are expected to start in 2018. 3. Entegris (ENTG) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Toshiya Hari citing the recent pullback in shares and maintained a $29 price target. 4. Blackstone (BX) upgraded to Buy from Neutral at Citi with analyst William Katz saying the company's intentions to raise a $40B infrastructure fund should be a "valuation catalyst." 5. Cree (CREE) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he thinks that the company's new CEO could make positive changes at the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/22/17
RAJA
05/22/17
UPGRADE
Target $95
RAJA
Outperform
Motorola Solutions upgraded to Outperform on valuation at Raymond James
Raymond James upgraded Motorola Solutions to Outperform from Market Perform and established a $95 price target. Analyst Tavis McCourt said shares look increasingly attractive based on improved demand visibility that is less economically sensitive than many of its peers, and demand catalysts from FirstNet buildouts that are expected to start in 2018.
05/26/17
JEFF
05/26/17
NO CHANGE
Target $100
JEFF
Buy
Jefferies feels 'very good' about risk/reward on Motorola Solutions
After looking into the company's business, Jefferies analyst George Notter says he feels "very good" about the risk/reward in shares of Motorola Solutions. The company is not seeing any slowdown in its Federal business, and management tends to set conservative expectations, Notter tells investors in a research note. He's still surprised that the guidance three weeks ago wasn't viewed more positively. The analyst reiterates a Buy rating on Motorola Solutions with a $100 price target.
LGF.A Lionsgate
$28.41

0.37 (1.32%)

07/21/17
07/21/17
NO CHANGE

Lionsgate price target raised to $36 from $29 at Loop Capital
Loop Capital analyst David Miller said that while Lionsgate shares have grinded higher as the company "continues to do what it has always done very well," he also has confidence that it is well ahead of plan on Starz synergies and that it has potential from "second-window" sales of streaming rights and orders from OTT platforms. Miller raised his price target on Lionsgate B shares to $36 from $29 and keeps a Buy rating on the name.
06/27/17
06/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Alex Yao resumed coverage of Alibaba (BABA) Group with an Overweight rating and $190 price target following a period of restriction. The rating is unchanged and the price target is raised from $140. 2. SunTrust analyst Terry Tillman initiated Salesforce (CRM) with a Buy and a $110 price target and views its as a core holding for large-cap investors. 3. Citi analyst Joel Beatty started Arena Pharmaceuticals (ARNA) with a Buy rating and $23 price target. 4. Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. 5. Cantor Fitzgerald analyst Louise Chen assumed coverage of Amarin (AMRN) with an Overweight rating and $10 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/17
DBAB
06/27/17
INITIATION
Target $29
DBAB
Hold
Lionsgate initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. The analyst views consensus estimates as too high but sees potential upside through consolidation.
06/02/17
06/02/17
UPGRADE
Target $31

Buy
Lionsgate upgraded to Buy at SunTrust
As previously reported, SunTrust upgraded Lionsgate (LGF.B) to Buy from Hold and raised its price target to $31 from $28. Analyst Matthew Thornton said expectations into the Q4 report were cautious as evidenced by the stock reaction to earnings, despite FY18 OIBDA guidance that was 3% below consensus. Now that FY18 OIBDA, Motion Pictures, and TV Production expectations have been re-based, Thornton believes estimates are now achievable, and said Starz's upcoming original releases should help sub growth near-term. The analyst said deleveraging is ahead of plan and could result in buybacks in FY19, and continues to expect ongoing consolidation of content and distribution, making Lionsgate a target given its assets and size.
BGS B&G Foods
$31.40

-0.3 (-0.95%)

08/07/17
BMOC
08/07/17
UPGRADE
BMOC
Outperform
B&G Foods upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Kenneth Zaslow upgraded B&G based on valuation. Target $39.
07/20/17
SBSH
07/20/17
UPGRADE
Target $43
SBSH
Buy
B&G Foods upgraded to Buy from Neutral at Citi
Citi analyst Cornell Burnett upgraded B&G Foods to Buy saying Q2 should mark a positive inflection in organic sales after five consecutive quarters of declines. The analyst projects flat organic sales, driven by strong growth in Green Giant, and views the current valuation as "cheap." Burnett keeps a $43 price target for the shares.
07/20/17
07/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Jay Sole saying the window to buy Nike is closing as earnings and North America sales growth rates are likely troughing. 2. B&G Foods (BGS) upgraded to Buy from Neutral at Citi with analyst Cornell Burnett saying the second quarter should mark a positive inflection in organic sales after five consecutive quarters of declines. 3. HP Inc. (HPQ) upgraded to Outperform from Sector Perform at RBC Capital with analyst Amit Daryanani saying he sees a "string of beats/raises" ahead amid stabilizing PC fundamentals and market share gains as Lenovo struggles. 4. Royal Caribbean (RCL) upgraded to Overweight from Neutral at JPMorgan with analyst Joseph Greff saying he views the current valuation as "undemanding" and notes his recent channel checks suggest continued good operating momentum. 5. Buffalo Wild Wings (BWLD) upgraded to Neutral from Underperform at Wedbush with analyst Nick Setyan saying investors understand that the company could report weaker than expected results and his other concerns about the company "are well understood." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/17
RBCM
07/25/17
NO CHANGE
RBCM
B&G Foods weakness overdone, says RBC Capital
RBC Capital analyst David Palmer says that B&G Foods' 15% decline this year is overdone. The analyst says that B&G's "category exposure may be better than peers," as it is more exposed to vegetables and spices, is the leader in Hispanic food categories and has "best in class spice manufacturing capacity." The analyst believes that scanner data understates the company's recent performance and outlook,. Additionally, he believes that its 5% dividend yield has "limited risk," The analyst keeps a $52 price target and an Outperform rating on the stock.
MDLZ Mondelez
$42.94

-0.47 (-1.08%)

08/03/17
WELS
08/03/17
NO CHANGE
WELS
Mondelez new CEO 'unconventional' but can 'inject fresh ideas,' says Wells Fargo
After Mondolez announced that its CEO would resign and named Dirk Van de Put as her successor, Wells Fargo calls the choice "unconventional." However, the firm thinks that, as an outsider, he will be able to "inject fresh ideas." Wells keeps an Outperform rating on the shares.
07/25/17
07/25/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mondelez (MDLZ) upgraded to Overweight from Neutral at Piper Jaffray with analyst Michael Lavery saying favorable sugar and cocoa costs provide a boost to margins. 2. Big Lots (BIG) upgraded to Buy from Hold at Deutsche Bank analyst Paul Trussell saying the current valuation is "compelling" given the disconnect between the company's "impressive" operating profit growth and multiple. 3. Werner (WERN) upgraded to Neutral from Underperform at BofA/Merrill with analyst Ken Hoexter saying truckload utilization and rates are turning positive. 4. Atlassian (TEAM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Sanjit Singh saying has increased confidence in expansion trends of the user base and said there are clear signs of pricing power, supporting 30% topline growth and 40% free cash flow CAGR over the next 3 years. 5. DSW (DSW) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the shares offer an "intriguing non-apparel value play." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
FBCO
06/19/17
NO CHANGE
FBCO
Hershey buy of Nestle assets could be type of 'poison pill,' says Credit Suisse
Credit Suisse analyst Robert Moskow analyzed several scenarios after Nestle's (NSRGY) recent announcement of a strategic review of its U.S. confectionery business. Buying Nestle candy would double Mondelez's (MDLZ) U.S. market share to 10%, but Moskow wonders if such a deal could compromise Mondelez' ability to eventually buy Hershey (HSY) at a later date. As for the latter, Hershey would generate "massive" synergies of 9% of sales and the deal could work as a type of "poison pill" to deter a bid from Mondelez or Kraft Heinz (KHC), said Moskow. However, he doesn't think Hershey would want to buy an asset that would dilute its topline growth rate at this point. He added that he sees "little to no chance" of Lindt, the number three in U.S. candy, being interested in Nestle's assets.
07/25/17
PIPR
07/25/17
UPGRADE
Target $49
PIPR
Overweight
Mondelez upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery upgraded Mondelez to Overweight and raised his price target for the shares to $49 from $48. Favorable sugar and cocoa costs provide a boost to margins, Lavery tells investors in a research note. The analyst expects the company's cash build will be applied to buybacks.
SRE Sempra Energy
$116.55

0.76 (0.66%)

06/08/17
LEHM
06/08/17
DOWNGRADE
Target $121
LEHM
Equal Weight
Sempra Energy downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Daniel Ford downgraded Sempra Energy (SRE) to Equal Weight with the shares close to his unchanged price target of $121. The analyst is increasingly concerned that the Cameron LNG export facility could face construction delays given the project's association with CB&I (CBI).
BRK.A Berkshire Hathaway
$267,377.00

302 (0.11%)

05/16/17
MSCO
05/16/17
NO CHANGE
Target $212
MSCO
Overweight
IBM at attractive entry point ahead of mainframe cycle, says Morgan Stanley
Morgan Stanley analyst Katy Huberty attributes recent weakness in shares of IBM (IBM) to the combination of the news that Warren Buffett's Berkshire Hathaway (BRK.A) cut its stake by a third and the company's weak Q1 gross margin trends. However, growth accelerates and margins expand historically for IBM around a mainframe cycle, making the pullback an attractive entry point, according to Huberty. The analyst, who sees a number of the gross margin pressures that have recently plagued IBM abating in the second half of 2017, has a $212 price target on Big Blue's shares.
07/12/17
LOOP
07/12/17
NO CHANGE
Target $42
LOOP
Buy
Core-Mark unlikely to 'get Amazoned,' says Loop Capital
Loop Capital analyst Andrew Wolf said he sees Core-Mark (CORE) as the least likely company among those he covers to get "Amazoned," or put at risk by Amazon (AMZN) buying a competitor. Its closest competitor McLane, which is owned by Berkshire Hathaway (BRK.B), is highly unlikely to sell to Amazon given that its largest customer is Amazon's rival Wal-Mart (WMT), Wolf tells investors. He keeps a Buy rating on Core-Mark and raised his target on the shares to $42 from $40 citing his increased 2018 EPS forecast.
06/27/17
06/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Impinj (PI) was downgraded to Sector Weight from Overweight by Pacific Crest analyst Brad Erickson based on valuation. 2. Mizuho analyst Haendel St. Juste downgraded Store Capital (STOR) to Neutral from Buy citing fair valuation following recent strength driven by Berkshire Hathaway's (BRK.A) investment. 3. Camtek (CAMT) was downgraded to Hold from Buy by Needham analyst Y. Edwin Mok, as he expects to see some deceleration as the PCB business normalizes and he believes large orders for back-end semi inspections are already reflected in the stock after its recent run-up. 4. Nomura Instinet analyst Dan Dolev downgraded Cintas (CTAS) to Neutral from Buy after lowering his FY18 uniform rental organic growth forecasts to 5% from 7%. 5. Atlantic Equities analyst Barry MacCarthy downgraded Hess Corp. (HES) and Schlumberger (SLB), both to Neutral from Overweight, given his view of the limited prospects for an oil price rebound. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/17
03/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monness Crespi analyst James Cakmak initiated Snap (SNAP) with a Buy and a $25 price target. 2. Workday (WDAY) initiated with a Buy at BofA/Merrill. 3. Berkshire Hathaway (BRK.A) initiated with an Equal Weight at Morgan Stanley. 4. MeetMe (MEET) initiated with a Buy at Canaccord. 5. ARC Document (ARC) resumed with a Buy at B. Riley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

, TSRO

Tesaro

$69.59

-2.07 (-2.89%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Recommendations
Heron Therapeutics, Tesaro analyst commentary  »

Tesaro update could drive…

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

TSRO

Tesaro

$69.59

-2.07 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:31
01/16/18
01/16
08:31
01/16/18
08:31
General news
Empire State Mfg Survey General Business Conditions Index data reported »

January Empire State Mfg…

LMOS

Lumos Networks

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Lumos signs multi-year contract with Roanoke Blacksburg Regional Airport »

Lumos Networks signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.60

1.94 (2.56%)

, BOBE

Bob Evans

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Options
One new option listing and three option delistings on January 16th »

New option listings for…

WP

Worldpay

$77.60

1.94 (2.56%)

BOBE

Bob Evans

SYT

Syngenta

VNTV

Vantiv

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAWK

Blackhawk

$36.50

-0.5 (-1.35%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Blackhawk 

Blackhawk trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$257.03

1.9 (0.74%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Marcus by Goldman Sachs now offering home improvement loans »

Marcus by Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

EIGR

Eiger BioPharmaceuticals

$16.00

0.65 (4.23%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Eiger BioPharmaceuticals »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 26

    Feb

  • 08

    Apr

GE

General Electric

$18.76

-0.26 (-1.37%)

08:29
01/16/18
01/16
08:29
01/16/18
08:29
Earnings
GE sees 2017 industrial operating & Verticals EPS at low end of $1.05-$1.10 »

Says "no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

, QGEN

Qiagen

$32.65

0.46 (1.43%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
HTG announces third statement of work for new clinical assay development program »

HTG Molecular Diagnostics…

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

QGEN

Qiagen

$32.65

0.46 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.17

-0.03 (-0.58%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
RedHill Biopharma's Phase II study of Bekinda met primary endpoint »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DERM

Dermira

$27.44

0.74 (2.77%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Recommendations
Dermira analyst commentary  »

Dermira should rally on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

SPB

Spectrum Brands

$120.48

-0.14 (-0.12%)

, ENR

Energizer

$51.62

0.15 (0.29%)

08:27
01/16/18
01/16
08:27
01/16/18
08:27
Conference/Events
Energizer to hold a conference call »

Management discusses the…

SPB

Spectrum Brands

$120.48

-0.14 (-0.12%)

ENR

Energizer

$51.62

0.15 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 29

    Jan

  • 30

    Jan

  • 31

    Jan

  • 08

    Feb

TPIC

TPI Composites

$20.98

0.28 (1.35%)

08:27
01/16/18
01/16
08:27
01/16/18
08:27
Initiation
TPI Composites initiated  »

TPI Composites initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WLL

Whiting Petroleum

$29.78

0.06 (0.20%)

08:26
01/16/18
01/16
08:26
01/16/18
08:26
Upgrade
Whiting Petroleum rating change  »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RILY

B. Riley Financial

$18.95

0.55 (2.99%)

08:26
01/16/18
01/16
08:26
01/16/18
08:26
Hot Stocks
B. Riley Financial acquires 29% of bebe stores »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$10.05

-0.45 (-4.29%)

08:25
01/16/18
01/16
08:25
01/16/18
08:25
Hot Stocks
Krystal Biotech granted patent for herpes simplex viral vectors »

Krystal Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$49.15

1.15 (2.40%)

08:25
01/16/18
01/16
08:25
01/16/18
08:25
Earnings
Avis Budget sees FY17 revenue about $8.85B, consensus 8.8B »

Avis Budget Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:25
01/16/18
01/16
08:25
01/16/18
08:25
General news
NY Empire State index preview: »

NY Empire State index…

CBT

Cabot

$67.24

0.84 (1.27%)

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Recommendations
Cabot analyst commentary  »

Cabot price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$80.51

0.15 (0.19%)

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Hot Stocks
Discover reports December charge-off rate 3.1% vs. 3.1% last month »

Reports December over 30…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BTC

Bitcoin

, BITCOIN

Bitcoin

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Periodicals
Bitcoin falls amid concerns over regulatory crackdown, Reuters reports »

Bitcoin has dropped 18%…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$39.43

0.78 (2.02%)

08:24
01/16/18
01/16
08:24
01/16/18
08:24
Recommendations
Aimmune analyst commentary  »

Aimmune Q1 data should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$14.35

0.45 (3.24%)

08:23
01/16/18
01/16
08:23
01/16/18
08:23
Conference/Events
Goldcorp to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

ATNX

Athenex

$15.87

0.15 (0.95%)

08:23
01/16/18
01/16
08:23
01/16/18
08:23
Hot Stocks
Athenex receives 'positive' feedback from FDA on design of Oraxol clinical trial »

Athenex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$205.33

1.56 (0.77%)

08:20
01/16/18
01/16
08:20
01/16/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.